High dose Chemotherapy and Autologous Stem Cell Transplantation for Poor Risk and Recurrent Non-Hodgkin’s Lymphoma: A Single-Center Experience of 50 Patients

BACKGROUND: The long-term survival of patients with non-Hodgkin’s lymphoma after conventional chemotherapy is about 35%, with the remaining 65% of patients tending to be refractory or experience relapse. As such, primary refractory patients responding to salvage chemotherapy, and sensitive relapsed...

Descripción completa

Detalles Bibliográficos
Autores principales: Shim, Byoung Yong, Lee, Myoung A, Byun, Jae-Ho, Roh, Sang Young, Song, Chi-Won, Park, Jin-No, Lee, Jong Wook, Min, Woo Sung, Hong, Young Seon, Kim, Chun Choo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Association of Internal Medicine 2004
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4531588/
https://www.ncbi.nlm.nih.gov/pubmed/15366643
http://dx.doi.org/10.3904/kjim.2004.19.2.114

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4531588/
https://www.ncbi.nlm.nih.gov/pubmed/15366643
http://dx.doi.org/10.3904/kjim.2004.19.2.114

Ejemplares similares